BAY1895344, another novel potent and selective ATR inhibitor, exhibits strong monotherapy efficacy in cancers, and synergistic activity in combination with DNA damage therapies.1265 A phase II clinical trial of BAY1895344 in patients with recurrent solid tumors (NCT05071209) is in progress. Here, ATR is linked to cancer.